3. Renin Angiotensin System (RAS) overview Renin-angiotensin system and cardiovascular risk Lancet 2007; 369: 1208–19

9. Angiotensin Receptor 1 (AT1) http://www.mpi-magdeburg.mpg.de/research/projects/1010/1014/neuron_modeling

10. Nature Reviews Drug Discovery 1 ; 621-636 (2002); doi:10.1038/nrd873

11. RAS and NOS Angiotensin II-nitric oxide interaction in the kidney Current Opi Nephrol Hypertens 16:61-51,2007

12. RAS and sympathetic regulation

15. RAS and Left Ventricular Hypertrophy

19. RAS and Atrial fibrillation

20. Risk of Atrial fibrillation Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure Journal of Hypertension 2007, 25:15–23

21. Large hypertension (HT) and heart failure (CHF) trials reporting new-onset atrial fibrillation Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure Journal of Hypertension 2007, 25:15–23

22. Preventive effects of angiotensin II-receptor blockers Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure Journal of Hypertension 2007, 25:15–23

23. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Am Heart J 2006;152:217222.)

24. Forest plot and RR of individual trial and summary pooled estimate. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Am Heart J 2006;152:217222.)

26. Possible preventive mechanisms Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure Journal of Hypertension 2007, 25:15–23

27. RAS and Stroke

28. Angiotensin and stoke Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure ( Stroke February 2004)

32. Cumulative incidence of cerebrovascular events (secondary endpoint) in patients in the MOSES study

34. RAS and Atherosclerosis

35. Renin-angiotensin system and atherosclerosis

37. Angiotensin II and Interleukin-18 ( Circ Res . 2005;96:1064-1071.)

40. Angiotensin and atheroslcerosis Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure ( Stroke February 2004)

41. Comparison of three large scale clinical trials examining the effect of ACE inhibition on cardiovascular events

42. Renin Angiotensin system and type 2 diabetes

44. New-onset diabetes in comparative outcome trials involving the use of RAS blockade versus non-RAS blockade Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes (Journal of Hypertension 2005, Vol 23 No 3 )

46. Risk of developing type 2 diabetes with ACE inhibitors or ARBs compared with other antihypertensive treatment

47. Change of albuminuria predicts occurrence of cardiovascular events and heart failure in patients with overt diabetic nephropathy Reproduced with permission from de Zeeuw D et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–27.143

48. Ｔ hanks for your attention

49. Exocytose by Angiotensin II Involves Multiple G-Protein-Regulated Transduction Pathways in Chromaffin Cells The Journal of Neuroscience, July 1, 2000, 20 (13):4776–4785